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DNA methylation markers predict recurrence-free interval in
triple-negative breast cancer
Mary Jo Fackler1, Soonweng Cho1,2, Leslie Cope1, Edward Gabrielson3, Kala Visvanathan1,4, Kathleen Wilsbach2,3, Danielle Meir-Levi1,
Charles F. Lynch5, Jeffrey Marks6, Joseph Geradts7,8, Meredith M. Regan9, Giuseppe Viale10, Antonio C. Wolff 1,
Saraswati Sukumar1,3* and Christopher B. Umbricht1,2,3*
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease
recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional
cohorts. Discovered marker sets were then tested by Kaplan−Meier analyses in a prospectively collected TNBC cohort of 49 samples
from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121
TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free
interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined
institutional and IBCSG chemotherapy cohorts (100 marker panel, p= 0.002; 30 marker panel, p= 0.05). Chromosome 19 sites were
enriched among these loci. In conclusion, our hypermethylation signatures identify increased recurrence risk independent of
whether patients receive chemotherapy.
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INTRODUCTION
Triple-negative breast cancers (TNBC) lack expression of the
estrogen (ER), progesterone (PR) and HER2 receptors. The TNBC
subtype represents ~15% of all breast cancers and is more
aggressive than other subtypes of breast cancer, with poorer
prognosis. In recent studies, the 5-year overall survival was 60%1
and the breast cancer-speciﬁc survival was 75%.2 The absence of
receptors renders TNBCs unresponsive to the targeted hormonal
and anti-HER2 therapies that are used in other breast cancers.
Unfortunately, none of the most widely used gene expression
proﬁling tests, the 21-gene Oncotype DX, the 70-gene Mamma-
print, or the PAM50, has clinical utility in patients with TNBC.3,4
On the other hand, combined data from several National
Adjuvant Surgical Breast and Bowel Project (NSABP) trials show
that in early disease, 80% of patients with ER-negative tumors
measuring 1 cm or less (T1a-b) treated with locoregional therapy
alone remained recurrence free at 8 years.5 Identiﬁcation of the
20% of early-stage TNBC tumors with more aggressive behavior
would provide two beneﬁts: (1) patients with less aggressive
disease could be managed more conservatively, and, (2) patients
known to have more aggressive disease could be selected for
more intensive and/or novel therapies at earlier stages of disease.
Similar to gene expression, global patterns of DNA methylation
in cancer can deﬁne distinct breast cancer subtypes6 with
important prognostic implications.7 Gene promoter methylation
is an important silencing mechanism for tumor suppressors and
associated regulatory genes,8 and dysregulation of DNA methyla-
tion is an early hallmark of cancer and has been well-documented
in in situ neoplasia as well as invasive and metastatic
carcinoma.9,10 It may be possible to exploit these features of the
disease to risk-stratify TNBC tumors.
The objectives of this study were to develop prognostic tools for
TNBC that can distinguish breast cancers with a favorable natural
history vs. those with a high risk of recurrence. We hypothesized
that methylated gene markers present in primary TNBC will help
identify: (1) the majority of early-stage patients (60%) whose
cancer will not recur after locoregional therapy alone, and
therefore may not beneﬁt from chemotherapy, and (2) those
who will draw beneﬁt from chemotherapy (20%), and (3) those
who will not beneﬁt (20%) and therefore need alternate treatment
approaches. Towards this goal we performed a genome-wide
search for DNA methylation markers using the available archival
tumor samples of node-negative TNBC from three institutions
(Johns Hopkins University, University of Iowa, Duke University) as
well as available samples from TNBC patients enrolled in
International Breast Cancer Study Group (IBCSG) Trials VIII and
IX.11 We required a minimum follow-up of 5 years post diagnosis,
and allowed both chemotherapy-treated and -untreated patients
with preplanned stratiﬁcation in this exploratory phase of assay
development (see consort diagram, Fig. 1).
RESULTS
Quality control (Q/C)
The overall Discovery strategy used to identify CpG loci associated
with recurrence is shown in Supplementary Fig. S1. The technical
performance for the array was assessed within GenomeStudio for
each sample by determining the percentage of detected CpG
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probes passing quality control (p ≤ 0.01) among the 485,577 array
probes (Supplementary Fig. S2). Mean call rates for the study
sample groups, Institutional NoChemo, Institutional Chemo, IBCSG
(NoChemo & Chemo), and Normal Breast sample set, were 95%,
96%, 87% and 98%, respectively. Samples deemed to be outliers
(≥2.5 SD from the mean) were removed from the study
(Supplementary Fig. S2).
The key clinical parameters for the resulting three study cohorts
(Institutional NoChemo, Discovery Set, N= 115; IBCSG NoChemo,
Test Set1, N= 50; Combined Chemo, Test Set2, N= 131) are
summarized in Table 1. As expected, NoChemo and Chemo
cohorts differed signiﬁcantly in age, tumor size, and use of
radiotherapy, while tumor grade did not.
Exploratory data analysis
Principal component analysis (PCA). Two principal component
analyses (PCA), incorporating all 460,772 array probes (Supple-
mentary Fig. S3a) and 59,581 cancer-speciﬁc probes (Supplemen-
tary Fig. S3b) respectively, were performed on the methylation
data of the Institutional NoChemo (Discovery) dataset to visualize
similarities between samples. While the ﬁrst three components
showed clear separation between tumor and normal samples,
recurrent and nonrecurrent tumors largely overlapped, indicating
most of the array probes were similarly methylated between
recurrence groups.
High differential methylation of candidate CpG loci detected in
recurrent tumors vs. nonrecurrent tumors in the Discovery set of
patients receiving no chemotherapy
Starting with the 59,581 cancer-speciﬁc CpG probes, we ranked
candidate recurrence-associated probes from highest to lowest
based on the MeanRatio in Partek Genomic Suites, calculated by
dividing the average methylation beta value within the recurrent
(R) group by that of the nonrecurrent (NR) group (MeanRatio= R/
NR), selecting the 100 most highly ranked probes for further
analysis (Table S1). Clinical utility depends on both intensity and
frequency of methylation of a marker in individual cancer and
normal tissues. Therefore, we inspected the distributions of
methylation levels for each of the 100 probes in both tumor
and normal breast samples. A total of 30 probes having β < 0.01 in
all normal breast samples, as well as β > 0.015 in at least 4 of 110
tumors, were identiﬁed as particularly promising candidates (Table
S1). Individual CpG methylation levels among genes in the panel
were added together within a sample to obtain a cumulative
methylation index (CMI) for each subject.
The relationship between CMI and recurrence in the Discovery
cohort, modeled using logistic regression, is shown in Fig. 2a, for
both the 100 and the 30 CpG probe panels. Fitted logistic
regression curves, describing the estimated probability of
recurrence for each methylation level, showed a strong associa-
tion of higher cumulative methylation levels of the gene marker
panel with recurrence (Fig. 2a1, Supplementary Tables S1 and S2).
High methylation is associated with increased probability of tumor
recurrence in patients who do not receive chemotherapy
To determine if the differentially methylated panels of 100 and 30
markers could identify a subgroup of TNBC patients who had good
outcomes without receiving chemotherapy, we evaluated the
nonchemotherapy arms of IBCSG Trials VIII & IX. The Kaplan−Meier
plot generated by comparing samples with high vs. low methylation
relative to the median showed that patient with high tumor
methylation had shorter recurrence-free intervals (RFI),12 although
data did not reach statistical signiﬁcance in this cohort with only 16
recurrences (Fig. 2b1, b2, Supplementary Fig. S4).
Fig. 1 Consort diagram showing sample sources and processing scheme for identiﬁcation of markers. Primary TNBC cancer samples from
the Discovery cohort (N= 110) (not given chemotherapy) were evaluated to identify DNA methylation markers high in recurring and low in
nonrecurring cancers. Candidate markers were then tested in the IBCSG No Chemo Test cohort (not given chemotherapy) (N= 49). Also
evaluated was the combined IBCSG and Institutional Chemo cohort (N= 120) obtained from patients who received chemotherapy. Cases that
recurred after 5 years and controls with less than 5 years of follow-up were excluded (5-year censoring).
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High methylation is associated with increased probability of tumor
recurrence in patients who receive chemotherapy
Our next step was to determine whether the same markers could
stratify TNBC patients who received chemotherapy, according to
risk of recurrence. For this purpose, we combined an institutional
chemo-treated set (N= 56, 20 cases and 36 controls) with data
from the IBCSG chemo-treated arm (N= 64, 6 cases and 58
controls), applying the same deﬁnition of case and control
according to 5-year, recurrence-free survival to both sets. Logistic
regression was used to model the relationship between DNA
methylation level and disease status at 5 years. We observed a
signiﬁcant association between high methylation and a recurrence
for the 100 marker panel (OR= 1.26, p= 0.004), while the
association was weaker for the 30 marker panel (OR= 1.30, p=
0.10) (Fig. 2d1, d2, Supplementary Fig. S4). Odds ratios were
similar for the institutional samples, evaluated separately (100
marker panel: OR= 1.34, p= 0.02; 30 marker panel: OR= 1.15,
p= 0.227) (Fig. 2c1, c2, Supplementary Fig. S4). With only six cases,
IBCSG chemo-treated samples were not evaluated separately.
Finally, when analyzed as single markers, 14 of the 30 CpG loci
showed signiﬁcant associations between high DNA methylation
and recurrence (Supplementary Table S2) for the combined
chemo-treated group. Incidental to these ﬁndings, we observed
that the number of CpG loci probes localizing to Chromosome 19
was enriched in our panels compared to the array as a whole. Only
5.3% of the array probes map to Chromosome 19, but the
recurrence panels of 100 and of 30 markers were enriched to 15
and 37% Chr. 19 probes, respectively (Supplementary Table S3).
Finally, all test samples in the NoChemo and Chemo groups
were evaluated together using a single median methylation array
value (β= 6.469) to deﬁne high vs. low methylation (Fig. 2e). In
this analysis, high methylation was associated with worse
outcome regardless of adjuvant chemotherapy, and chemother-
apy improved outcome regardless of methylation levels. The
observed narrowing of the curves at high cumulative methylation
values, where probability of progression was highest, may suggest
a better response to chemotherapy in low methylation cancers,
but there are too few data points supporting the model in the
high methylation range to draw conﬁdent conclusions.
Cross-platform technical array validation
To ensure accuracy of our array data obtained from archival tissue,
we used an alternative assay, QM-MSP, to measure DNA
methylation levels for a subset of the markers. Using 42 of the
50 IBCSG NoChemo samples, including 12 recurrences, we
compared results between QM-MSP and the array for 9 markers
that had frequent array hypermethylation in both the Discovery
Set and IBCSG NoChemo Test Set. The QM-MSP results paralleled
that of the methylation array, with a Spearman correlation
coefﬁcient of r= 0.495 (p= 0.0009) (Supplementary Fig. S5).
DISCUSSION
The purpose of this study was to investigate whether DNA
methylation patterns might stratify TNBCs into clinically actionable
risk categories using available clinical samples of convenience for
which long-term outcomes were well documented. The primary
analysis included TNBC patients who received only locoregional
therapy, after which the ﬁndings were extended to include
patients treated by chemotherapy as well.
We identiﬁed a set of 100 candidate CpG marker sites, as well as
a more selected set of 30 marker sites, in which higher levels of
methylation were associated with greater probability of 5-year
recurrence following locoregional therapy. In both panels, high
levels of methylation were associated with worse outcome in
independent samples from patients enrolled in IBCSG Trials VIII
and IX, who received locoregional treatment but no chemother-
apy, although results did not reach statistical signiﬁcance.
We further tested our candidate markers in samples from
patients who received chemotherapy as well as locoregional
treatment. Like the locoregionally treated samples, these included
patients from the chemo-treated arms of IBCSG Trials VIII and IX, as
Table 1. Characteristics of the primary TNBC breast cancer patients in the study.
Characteristics Discovery set
No chemotherapy
IBCSG test set
No Chemotherapy
IBCSG/JHU test set
Chemotherapy
Total N= 115 N= 50 N= 68+ 63
Cases (with recurrences) (n) 53 10+ 23
Controls (no recurrences) (n) 62 58+ 40
Recurrence-free interval (median months) 125
Age (median) 63 54 50 F= 34.87, p < 0.00001
AJCC stage χ2= 41.51, p < 0.00001
I 29 7 13+ 19
II 48 42 55+ 31
III 2 0 0+ 13
NA 36 1 0
Tumor stage χ2= 13.84, p= 0.0078
1 14 26 44
2 35 19 77
3 0 5 10
NA 65 1 0
Grade χ2= 3.60, p= 0.46
1 0 0 2
2 9 19 18
3 41 78 111
NA 18 0 0
Radiation therapy (n) 33 19 64 χ2= 10.48, p= 0.0053
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well as institutional samples of convenience. The samples were
combined and analyzed as one case−control cohort using logistic
regression to model the relationship between DNA methylation
and 5-year recurrence. Again, higher levels of methylation were
associated with an increased probability of recurrence, with the
result achieving statistical signiﬁcance this time.
The 30 CpG marker panel appeared to have less discriminatory
power compared to the 100 marker panel, which may be a
reﬂection of the well-documented heterogeneity present in
TNBC,13 indicating that adequately characterizing TNBC will
require broad molecular signatures. The 30 CpG loci were
enriched in genes that demonstrate DNA binding and transcrip-
tion regulatory functions, and Chromosome 19-speciﬁc probes
were enriched among the 100 and 30 CpG marker sets compared
to the array as a whole (see Supplementary Table S3).
Finally, we ﬁt a multivariate logistic regression model, including
both chemo- and locoregionally treated samples, to answer our
primary question of whether the potential beneﬁts of chemother-
apy varied by methylation level. We found that patients
consistently beneﬁt from chemotherapy across the entire range
of methylation levels, results that support the current, standard
practice of providing adjuvant chemotherapy to all TNBC patients.
The strengths of our study include assembling a set of now rare,
TNBC cases treated without chemotherapy, the availability of
robust long-term outcome data, as well as samples from mature
international randomized controlled trials, and the comprehen-
sive, genome-wide analysis of DNA methylation in this study.
Limitations include the retrospective analysis of a heterogeneous
set of samples from several sources, necessary to complement the
small number of recurrences observed in IBCSG trials VIII and IX,
and the inability to adjust for clinicopathologic covariates. It was
therefore encouraging to see that results were comparable across
our diverse cohorts, including in the chemotherapy arms of our
institutional samples and IBCSG trial samples.
In summary, our ﬁnding of a repeated association between
methylation patterns and long-term outcome suggest that further
exploration of their potential to better risk-stratify patients in well-
characterized TNBC datasets may be warranted. We have
identiﬁed patterns of methylation that are associated with
prognosis among patients with TNBC, although they are at
present not predictive of response to local-regional or systemic
therapy. While these ﬁndings cannot be exploited to improve
clinical decision making today, our results, and the underlying
data, collected on an increasingly rare group of TNBC patients
treated with locoregional therapy alone, are a valuable contribu-
tion to ongoing research on the development, progression and
ultimate treatment of TNBC.
METHODS
Informed consent
All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards.
Women enrolling in the study signed an informed consent approved by
the Institutional Review Boards of participating institutions (Johns Hopkins
University, Duke University, University of Iowa). For IBCSG study samples,
institutional review boards reviewed and approved the protocols, and
informed consent was required according to the criteria established within
the individual countries.
Sample selection
This study was designed and reported in accordance with REMARK
guidelines.14 Our experiment required at least 75 cases and 75 controls in
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Fig. 2 Logistic regression plots demonstrate the relationship between the probability of recurrence vs. high cumulative methylation
levels of the panel of 100 CpG markers, and 30 CpG marker subset, identiﬁed using the Discovery cohort. Sample cumulative methylation
is deﬁned for the marker panel as the sum of beta methylation (β value, the level of CpG locus methylation, low to high ranging from 0 to 1,
respectively for each marker in the panel). Cases (recurrences, upper x-axis) and controls (no recurrences, lower x-axis) are shown as colored
circles. The association between methylation level and probability of recurrence (y axis), at 1.0 and 0.0 probabilities respectively, is
demonstrated in plots (a, c–e). The likelihood of recurrence increased in proportion to the level of cumulative methylation, as seen in cohorts
from the Discovery (a1–a2, No Chemo), Institutional (c1−c2, Chemo; p= 0.020, 100 marker panel), and Institutional+ IBCSG (d1−d2,
Combined Chemo; p= 0.002, 100 marker and p= 0.050, 30 marker sets), using each group’s median methylation as the threshold value. The
overlay of regression plots (E1) derived from the IBCSG No Chemo cohort (pink, upper line) and the IBCSG/Institutional Combined Chemo
cohort (blue) shows similar upward slopes suggesting that the association between high methylation and increased risk is independent of
chemotherapy. The Kaplan−Meier plot of the IBCSG Test Set (b1−b2, No Chemo) displays the relationship between high methylation (red,
lower line) and shorter recurrence-free survival, compared to low methylation (blue).
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the discovery phase as well as at least 83 trial samples for validation. The
discovery phase had to provide adequate power for candidate marker
discovery and the validation phase had to permit precise estimation of
marker performance. Simulations show that with 75 samples per group,
and the false discovery rate (FDR) controlled at no more than 10%, we
expect to identify the majority of sites (62%) differentially methylated at a
moderate effect size of 0.75 SD and virtually all (98%) of those with an
effect size of 1.0 SD. Moreover, the 95% lower conﬁdence bound on
sensitivity/speciﬁcity will be within 0.1 of the estimate. With 83 samples,
the validation study would be powered to detect a hazard ratio of 2.3
between patients with high- and low-risk methylation proﬁles, correspond-
ing to 10-year survival of approximately 60% and 80% respectively, based
on long-term survival rates for locoregionally and systemically treated
TNBC. Moreover, the 95% lower conﬁdence bound on sensitivity/speciﬁcity
will be within 0.1 of the estimate. The number of available TNBC samples
meeting our selection criteria for patients receiving only locoregional
therapy (see Fig. 1) was, however, very limited after the publication of
studies documenting the beneﬁts of adjuvant chemotherapy in TNBC.
While the ultimately available IBCSG samples included fewer recurrence
events than speciﬁed in our design, we continued because of the need for
improving our understanding of TNBC and because material from
locoregionally treated TNBC tumors would only become more difﬁcult to
obtain in the future.
The consort diagram shows our sample selection and quality control (Q/
C) process (Fig. 1). Formalin-ﬁxed parafﬁn-embedded (FFPE) tissues of
node-negative primary TNBC, stages 1–3, were obtained after review of
pathology tissue archives and clinical reports from collaborating labora-
tories at Johns Hopkins University (JHU), Duke University Medical Center,
and the State Health Registry of Iowa, with approval of the respective
Institutional Review Boards, as institutional cases and controls. The
institutional tissue blocks were collected over a 25-year period
(1985–2009). Samples were also accessed from residual materials from
The International Breast Cancer Study Group (IBCSG) Randomized Clinical
Trials VIII and IX,11 after approval of the International Breast Cancer Study
Group Biological Protocols Working Group (Table 1).
Many of the tissue samples obtained for this study predate the
availability of standardized assays for HER2 status, and the deﬁnition of
hormone receptor status changed over time as well. For all IBCSG samples,
we relied on the centralized ER and HER2 assessment available from
IBCSG.11 For institutional samples, we accepted the original classiﬁcations
provided in the ofﬁcial pathology reports of the respective institutions. For
samples predating routine HER2 assessment, we performed a transcrip-
tome analysis using the Illumina DASL arrays15 to detect HER2 transcript
expression. HER2 positivity was assigned using the Q3+ 1.5*IQR (inter-
quartile range) rule identifying HER2 outliers.
Institutional cases were deﬁned as those with local, regional or distant
recurrence, which occurred between 6 months and 5 years after initial
diagnosis but excluded contralateral breast cancer. Controls were those
with no recurrence, with a minimum follow-up of 5 years. Cases that
recurred after 5 years and controls with less than 5 years of follow-up were
excluded (5-year censoring). The same criteria were applied to the IBCSG
samples. Institutional controls were matched to cases by age and date of
diagnosis within 5 years, AJCC (eighth edition) stage, and radiotherapy as
ﬁrst course therapy. Samples from patients that received no chemotherapy
(NoChemo) were analyzed separately from those receiving chemotherapy
(Chemo), but speciﬁc chemotherapy regimens (CMF for IBCSG, CMF and
Anthracycline/Taxane regimens for institutional samples) were not further
stratiﬁed for the institutional sets. Samples with incomplete data were
removed from the analysis. Similarly, use of hormonal agents was not used
to stratify the cohorts since they have not been shown to affect outcome
in TNBC. Additionally, ﬁve FFPE samples of normal breast tissue obtained
from JHUSOM Surgical Pathology were processed in parallel.
This approach resulted in four sets of samples (see Fig. 1): the
Institutional NoChemo set (N= 150, with 110 passing all array Q/C and
5-year censoring), used for initial marker discovery; the IBCSG NoChemo
set (N= 76, 49 passing Q/C and 5-year censoring); the IBCSG Chemo set
(N= 99, 64 passing Q/C and 5-year censoring); and the Institutional Chemo
set (N= 69, 56 passing Q/C and 5-year censoring).
Candidate methylation markers identiﬁed in the NoChemo discovery
cohort were then independently validated on the IBCSG NoChemo dataset,
and separately on a Chemo dataset combining available Institutional and
IBCSG Chemo samples (N= 64+ 56= 120).
Genomic DNA extraction, sodium bisulﬁte conversion, and
template quality control (Q/C)
All study samples were assigned internal codes and all laboratory analyses
were performed in a blinded fashion with regard to sample outcomes.
FFPE tumor tissue sections (Institutional samples, two 10 μm sections with
>50% tumor, macrodissected as necessary) or one tumor-targeted core of
FFPE (IBCSG samples, 0.6 mm× 2mm) were deparafﬁnized with xylene,
digested for 24 h at 56 °C with 10mM Tris pH 8, 150mM NaCl, 2 mM
ethylenediaminetetraacetic acid (EDTA), 0.5% sodium dodecyl sulfate (SDS)
containing 4mg proteinase K, and heated to 90 °C for 10min. The EZ DNA
Methylation kit (D5001; ZymoResearch) was used for bisulﬁte conversion.
Bisulﬁte-treated genomic DNA was restored (375 ng in 10 µl; Inﬁnium HD
FFPE DNA Restore Kit; WG-321-1002, Illumina, Inc.) and arrayed using the
Illumina Inﬁnium HumanMethylation450K BeadChip Kit (WG-314-1003) in
the JHU DNA Microarray Core. Prior to hybridization, DNA quality was
veriﬁed by Nanodrop, and samples with less than 300 ng DNA were
rejected. After samples were arrayed, the amount of hybridized DNA on
the array was evaluated by comparing the total signal of methylated and
unmethylated DNA to background levels at each CpG locus. High, locus-
speciﬁc detection p values (p > 0.01) indicate low DNA levels, poor quality of
DNA, or otherwise poor probe performance. Samples were rejected that
had too many poorly performing probes (>2.5 standard deviations below
the mean % probes passing QC; see Fig. S1).
Quantitative multiplex methylation-speciﬁc PCR (QM-MSP)
QM-MSP16 primer/probe sets were designed to hybridize to a region
overlapping or within 100 bp of the target sequence for the 50 bp array
probe of interest. Individual gene methylation (M) is calculated as
%Mgene ¼ #methylated copiesð Þð#methylatedþ unmethylated copiesÞ ½100. Cumulative methylation
index (CMI)= sum of % M for all genes.16
Statistical analysis
Raw array ﬁle data were imported into Illumina GenomeStudio v2011.1
(Illumina, Inc, San Diego, CA) without normalization. Probe hybridization
and quality control were assessed within GenomeStudio, as was the level
of CpG locus methylation, calculated as a β value, low to high ranging from
0 to 1, respectively. Distributions of methylation levels were visualized
using histograms. Data were then imported into the Partek Genomics Suite
(Partek, Inc, St. Louis, MO) and analyzed using standard Partek functions as
well as GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA) tools. A set of
59,581 CpG sites with a tumor/normal mean β value ratio ≥1.5 were
designated as cancer-speciﬁc and evaluated separately in some of the
subsequent analyses. The selection of high tumor/normal β value ratios
minimizes the contribution of benign tissue and variable sample purity to
the cumulative methylation index.
Log rank (Mantel−Cox) tests were used to evaluate associations between
DNA methylation levels and recurrence in IBCSG trial data. Because our
institutional, case−control cohorts are selected for outcome, they do not
reﬂect the natural history of disease and estimation of hazards would be
inappropriate. Accordingly, logistic regression analysis was used to analyze
institutional, and mixed, IBCSG/Institutional datasets. For the mixed analysis,
the trial data were converted to cases vs. controls by classifying them
according to recurrence status at the 5-year mark. Models were ﬁt without
adjustment for clinical covariates, in consideration of the risk of over-ﬁtting
a complex model on a moderately sized dataset. We also note that adjuvant
chemo is the current standard of care for TNBC under a very broad
spectrum of clinical parameters, suggesting that clinical covariates we can
consider have limited use in this situation. Kaplan−Meier curves, logistic
regression curves and boxplots, and Mann−Whitney tests were used to
visualize associations and compare recurrence groups. Selected markers
were evaluated by Quantitative Multiplex Methylation-Speciﬁc PCR (QM-
MSP) to verify the methylation measures obtained by array, and results
were compared using Spearman correlation. All tests were two-tailed and
p < 0.05 was considered signiﬁcant.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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DATA AVAILABILITY
The data that support the ﬁndings of this study that were derived from Institutional
patient samples are available through the GEO repository at https://identiﬁers.org/
geo:GSE141441 (2019). All data derived from IBCSG study samples have been
deposited with the IBCSG Statistical Center. Access to IBCSG-derived datasets are
contingent upon IBSCG review and approval, for which a Data Use Agreement may
be required. To request access to data, contact the IBCSG Statistical Center
(stat_center@ibcsg.org). The IBCSG requires notiﬁcation and opportunity to review
before any public dissemination of results. The data generated and analyzed during
this study are described in the following data record: https://doi.org/10.6084/m9.
ﬁgshare.11378790.17
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